Riskpilot← Back to searchSign inGet full accessRL Oculist AB
ABActiveOrg 5590940846Blåklintsvägen 5Medical specialists activities · NACE 8622Est. 20162 employees
Revenue 2025
SEK 2,2M
+23% vs 2024
EBITDA margin
45.2%
+49% vs 2024
Equity ratio
72.1%
Financial strength
Net profit 2025
SEK 609K
+73% vs 2024
| Revenue | SEK 2,2M | +23% |
| EBITDA | SEK 977K | +49% |
| Net profit | SEK 609K | +73% |
| Total assets | SEK 993K | +33% |
| Equity | SEK 716K | +29% |
| Employees | 2 | — |
Legal name
RL Oculist AB
Org number
5590940846
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
23 december 2016
Share capital
SEK 50 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-05-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Föremålet för bolagets verksamhet är att arbeta som läkare inom vård och omsorg samt idka värdepappershandel och därmed förenlig verksamhet.
Address
Blåklintsvägen 5
Email
larinro@yahoo.co.uk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 2 044 | 1 966 | 2 043 | 1 758 | 2 160 |
| Staff expenses | — | −1 282 | −1 122 | −1 104 | −1 183 |
| EBITDA | 779 | 684 | 922 | 654 | 977 |
| Depreciation & amort. | −10 | −127 | −60 | −53 | −44 |
| EBIT | 769 | 411 | 730 | 435 | 772 |
| Net financials | — | −1 | −1 | 0 | −0 |
| Profit before tax | 769 | 410 | 729 | 435 | 772 |
| Tax | −170 | −62 | −164 | −82 | −163 |
| Net profit | 599 | 349 | 565 | 353 | 609 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 188 | 915 | 941 | 745 | 993 |
| Equity | 712 | 533 | 632 | 555 | 716 |
| Long-term debt | 0 | — | — | 14 | 0 |
| Short-term debt | 476 | 382 | 309 | 176 | 277 |
| Total debt | 476 | 382 | 309 | 190 | 277 |
EBITDA margin
45.2%
This company
15.8%
Market median
+186% vs market
20212025
Equity ratio
72.1%
This company
38.2%
Market median
+89% vs market
20212025
Return on equity
85.1%
This company
18.4%
Market median
+362% vs market
20212025
Net profit margin
28.2%
This company
8.1%
Market median
+248% vs market
20212025
Asset turnover
2.18×
This company
1.12×
Market median
+95% vs market
20212025
Debt / equity
0.39×
This company
0.62×
Market median
+37% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-06-01 – 2025-05-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-06-01 – 2024-05-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-06-01 – 2023-05-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-06-01 – 2022-05-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-06-01 – 2021-05-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of RL Oculist AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Efim Ionidis | Deputy Board Member | 0 companies |
| Roman Larin | Board of Directors | 0 companies |